Japanese collaboration to develop cell therapy for liver cirrhosis

14 September 2018

Osaka, Japan-based firms Shionogi (TYO: 4507) and Rohto Pharmaceutical (TYO: 4527) have agreed to work together on the Japanese development and possible future commercialization of ADR-001, a candidate for the treatment of liver cirrhosis.

Under the terms of the agreement, Shionogi will head up clinical development following an ongoing Phase I/II study in patients with decompensated liver cirrhosis. The firm will also be responsible for commercialization of ADR-001 for liver cirrhosis in Japan.

Rohto will receive an upfront payment and additional development milestones and royalties.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK